Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for reducing heavy drinking in alcohol dependence
2016-003343-11Phase 2Terminated
- Sponsor
- Psychiatric Centre Copenhagen
- Start
- Jan 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol dependence comparing Bydureon with Placebo (2 arms). Primary endpoint: Percent reduction in total number of heavy drinking days. Started Jan 2017; status: terminated.
02
Drugs
exenatide
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on 2016-003343-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003343-11.